Claims
- 1. A compound of formula I
- 2. A compound of claim 1 in which R1 and R2 are, independently, hydrogen, halo, cyano, carboxamido, trifluoromethyl, amino, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms.
- 3. A compound of claim 1 wherein R1 is alkoxy of 1 to 6 carbon atoms.
- 4. A compound of claim 1 wherein R1 and R2, taken together form methylenedioxy, ethylenedioxy or propylenedioxy.
- 5. A compound of claim 1 in which R1 is attached to position 8 of a chroman moiety.
- 6. A compound of claim 1 in which R3, R4, R5 and R7 are independently selected from hydrogen, halo, cyano, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms.
- 7. A compound of claim 1 wherein R3, R4, R5 and R7 are independently selected from hydrogen, halogen or cyano.
- 8. A compound of claim 1 wherein R6 is hydrogen or alkyl of 1 to 3 carbon atoms.
- 9. A compound of claim 1 wherein X is CR7.
- 10. A compound according to claim 1 wherein R7 is hydrogen, halogen or cyano.
- 11. A compound of claim 1 wherein n is 0 or 1.
- 12. A compound of claim 1 wherein the dotted line in the azaheterocycle represents a double bond
- 13. A compound of claim 1 in which R1 and R2 are, independently, hydrogen, halo, cyano, carboxamido, trifluoromethyl, amino, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms; R3, R4, R5 and R7 are independently selected from hydrogen, halo, cyano, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms; n is an integer 0 or 1; or a pharmaceutically acceptable salt thereof.
- 14. A compound of claim 1 in which R1 is alkoxy of one to six carbon atoms and is attached to position 8 of a chroman moiety, R2 and R4 are hydrogen, R3, R5 and R7 are independently selected from hydrogen, halo or cyano, X is CR7, n is 0 and the dotted line in the azaheterocycle represents a double bond; or a pharmaceutically acceptable salt thereof.
- 15. The compound of claim 1 which is 2-{[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-4-piperidinyl]methyl}-5-fluoro-1H-indole or a pharmaceutically acceptable salt thereof.
- 16. The compound of claim 1 which is 3-[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indole or a pharmaceutically acceptable salt thereof.
- 17. The compound of claim 1 which is 3-[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-5-fluoro-1H-indole or a pharmaceutically acceptable salt thereof.
- 18. The compound of claim 1 which is 5-fluoro-3-(1-{[8-methoxy-3,4-dihydro-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 19. The compound of claim 1 which is (3-(1-{[8-methoxy-3,4-dihydro-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 20. The compound of claim 1 which is 3-[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-6-fluoro-1H-indole or a pharmaceutically acceptable salt thereof.
- 21. The compound of claim 1 which is 6-fluoro-3-(1-{[8-methoxy-3,4-dihydro-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 22. The compound of claim 1 which is 5-fluoro-3-(1-{[8-methoxy-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 23. The compound of claim 1 which is 3-(1-{[8-methoxy-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 24. A method of treating a subject suffering from a condition selected from the group consisting of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 25. A method of claim 18 wherein the condition is depression.
- 26. The method of claim 18 wherein the condition is obsessive compulsive disorder, panic attacks, generalized anxiety disorder or social anxiety disorder.
- 27. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
BACKGROUND OF THE INVENTION
[0001] This application claims priority from copending provisional applications Serial No. 60/328,120, filed Oct. 9, 2001, Serial No. 60/327,417, filed Oct. 5, 2001, and No. 60/327,400, filed Oct. 5, 2001, the entire disclosures of which are hereby incorporated by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60328120 |
Oct 2001 |
US |
|
60327417 |
Oct 2001 |
US |
|
60327400 |
Oct 2001 |
US |